IDEAYA's Darovasertib Combo Meets Primary Endpoint in Melanoma Trial, Targets H2 2026 NDA

summarizeSummary

IDEAYA Biosciences announced positive topline results from its Phase 2/3 registrational trial for darovasertib in metastatic uveal melanoma, meeting the primary endpoint of progression-free survival and showing strong overall response rates, with an NDA submission targeted for H2 2026.

check_boxKey Events

• Positive Phase 2/3 Trial Results

  The darovasertib combination met the primary endpoint of statistically significant improvement in median progression-free survival (PFS) in first-line metastatic uveal melanoma.

• Strong Efficacy Data

  Patients treated with the combination reduced their risk of disease progression by 58% (HR 0.42), achieving a median PFS of 6.9 months versus 3.1 months for the control arm. The overall response rate (ORR) was 37.1% compared to 5.8% in the control arm, with 5 complete responses observed.

• Favorable Safety Profile

  The darovasertib combination was generally well-tolerated with a manageable safety profile consistent with prior reported results.

• Targeted NDA Submission

  Based on these data, IDEAYA plans to submit a New Drug Application (NDA) to the U.S. FDA in the second half of 2026.

auto_awesomeAnalysis

This 8-K reports highly positive topline results from the OptimUM-02 Phase 2/3 registrational trial for darovasertib in combination with crizotinib for metastatic uveal melanoma. The trial successfully met its primary endpoint, demonstrating a statistically significant improvement in progression-free survival and a substantial increase in overall response rates, including complete responses. This strong clinical data significantly de-risks the program and provides a clear path to market, with the company targeting an NDA submission in the second half of 2026. The positive news comes as the stock is already trading above its 52-week high, indicating strong investor confidence which these results are likely to reinforce.